Novo Nordisk A/S ADR (NVO)

$46.63 +0.24 (0.52%)
Market Cap 210.61B
Revenue (ttm) 46.79B
Net Income (ttm) 15.51B
EPS (ttm) N/A
PE Ratio 11.87
Forward PE 14.09
Profit Margin 33.14%
Debt to Equity Ratio 0.72
Volume 7,579,982
Avg Vol 12,432,314
Day's Range N/A - N/A
Shares Out 4.47B
Stochastic %K 50%
Beta 0.76
Analysts Hold
Price Target $47.48

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 45 44 44 88 88
Address:
Novo Alle 1, Bagsvaerd, Denmark
Ad7777
Ad7777 Aug. 13 at 7:33 PM
$NVO x dividends fri.
0 · Reply
Jtlo
Jtlo Aug. 13 at 7:22 PM
$NVO wegovy baby shag daddy is here to turn things around
0 · Reply
Pfiffer
Pfiffer Aug. 13 at 7:22 PM
$NVO powerhour
0 · Reply
Jtlo
Jtlo Aug. 13 at 7:15 PM
$NVO 12 months don't shake me out. My girl on too much novy and look hella fine for me to be broke
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 6:11 PM
$LXRX $NVO $VTRS Dr Edelman is total proponent of Zynquista for T1 - A towering authority in his field, that completely has our back = $LXRX
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 5:19 PM
$LXRX watch: Lexicon is exhibiting at TCOYD [Taking Control Of Your Diabetes] ONE 2026, Aug 14-16, San Diego. TCOYD is led by Dr. Steve Edelman (Founder/Director, UCSD Prof. of Medicine) and Dr. Jeremy Pettus (UCSD Assoc. Prof.) — independent physicians, not Lexicon staff, but longtime T1D [type 1 diabetes] advocates for options beyond insulin. Fresh catalyst: on Lexicon's Q2 2026 call, mgmt said STENO1 (Steno Diabetes Center, Denmark) is nearing the exposure threshold FDA flagged as sufficient for NDA [New Drug Application] resubmission of Zynquista (sotagliflozin) in T1D. Exposure expected by end of Aug 2026; DKA [diabetic ketoacidosis] rates similar to standard-of-care, below earlier trials. Resubmission targeted Q4 2026. Watching conference + STENO1 data into Q4. NFA. DYOR. https://www.linkedin.com/posts/lexicon-pharmaceuticals_lexicon-t1d-dpnp-activity-7493668586708885504-LpTh?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA $VTRS $NVO
0 · Reply
HerrBroekman
HerrBroekman Aug. 13 at 4:46 PM
$NVO bought some jan calls here
0 · Reply
Makingmillions192
Makingmillions192 Aug. 13 at 4:36 PM
$LEXX PegBio is not a tiny micro-cap shell company or early-stage startup—they are a $300M+ market-cap GLP-1 drug owner with a newly approved commercial molecule and US clinical trials. Having a funded partner evaluating DehydraTECH for their portfolio gives Lexaria substantial real-world validation. Hold onto your seats ladies and gentlemen. Lexaria is here 🔥 $VKTX $LLY $RANI $NVO
0 · Reply
Makingmillions192
Makingmillions192 Aug. 13 at 4:31 PM
🚀 $LEXX BOOOOM! 🚨 SECOND GLP-1 MTA CONFIRMED! 🚀 This is NOT a drill. Lexaria just dropped a game-changer! Entered into a brand-new Material Transfer Agreement (MTA) with PegBio to process their proprietary GLP-1 molecule via DehydraTECH! 🔥 THE HIGHLIGHTS: 1️⃣ Separate & Independent: This is IN ADDITION to the existing MTA partner. DehydraTECH pipeline is expanding! 2️⃣ Commercial Validation: PegBio has a GLP-1 approved in China (Nov 2025) + Phase 2 assets in US/China across Obesity, Diabetes, & MASH! 3️⃣ Liberi Group BD Delivering: The advisory strategy is executing in REAL TIME. Human trial data drops any day now ⏰ TICK TOCK 💥 🧨 Sub-1.65M float + massive BD validation + Study #7 data dropping next! We are SO BACK! 📈🔥 $VKTX $LLY $NVO $PFE
0 · Reply
Eddyg987
Eddyg987 Aug. 13 at 4:00 PM
$NVO ok at this point it doest look like it's going to move until next earnings, getting out until I see movement.
0 · Reply
Latest News on NVO
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Thu, 13 Aug 2026 13:00:00 -0400 - 2 hours ago

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)

2026-08-13T14:52:11.000Z - 5 hours ago

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)

LLY

Novo Nordisk Stock (NVO) Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly

2026-08-13T12:43:16.000Z - 7 hours ago

Novo Nordisk Stock (NVO) Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly

LLY

Novo CEO says obesity market won't be winner-take-all battle with Lilly

Thu, 13 Aug 2026 06:01:53 -0400 - 9 hours ago

Novo CEO says obesity market won't be winner-take-all battle with Lilly

Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

Wed, 12 Aug 2026 20:04:45 -0400 - 19 hours ago

Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

Wed, 12 Aug 2026 18:53:21 -0400 - 21 hours ago

Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

Wed, 12 Aug 2026 12:11:48 -0400 - 1 day ago

Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

2026-08-12T14:56:50.000Z - 1 day ago

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

PHARMA BETS: CEO turns to AI for next-generation drugs

Wed, 12 Aug 2026 10:30:00 -0400 - 1 day ago

PHARMA BETS: CEO turns to AI for next-generation drugs

Novo Nordisk Stock: Buy or Sell?

Tue, 11 Aug 2026 22:42:05 -0400 - 1 day ago

Novo Nordisk Stock: Buy or Sell?

Better Buy: Eli Lilly vs. Novo Nordisk

Tue, 11 Aug 2026 20:00:00 -0400 - 1 day ago

Better Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.

2026-08-11T09:27:44.000Z - 2 days ago

Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.

Novo Nordisk A/S Q2 Earnings Call Highlights

Sat, 08 Aug 2026 18:05:10 -0400 - 4 days ago

Novo Nordisk A/S Q2 Earnings Call Highlights

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Fri, 07 Aug 2026 18:30:00 -0400 - 5 days ago

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

2026-08-07T19:28:00.000Z - 6 days ago

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

2026-08-07T16:41:44.000Z - 6 days ago

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

Novo Nordisk price target lowered to DKK 310 from DKK 330 at Citi

2026-08-07T10:45:36.000Z - 6 days ago

Novo Nordisk price target lowered to DKK 310 from DKK 330 at Citi

Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market

2026-08-06T21:52:46.082Z - 6 days ago

Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market

Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk

2026-08-06T19:01:06.000Z - 7 days ago

Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk

Why Is Everyone Talking About Novo Nordisk?

Thu, 06 Aug 2026 15:00:00 -0400 - 7 days ago

Why Is Everyone Talking About Novo Nordisk?

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

Thu, 06 Aug 2026 09:45:29 -0400 - 7 days ago

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

33 stocks to bet on foreign markets continuing to beat the S&P 500

Thu, 06 Aug 2026 07:30:00 -0400 - 7 days ago

33 stocks to bet on foreign markets continuing to beat the S&P 500

Novo Nordisk price target raised to $47 from $45 at BMO Capital

2026-08-06T11:25:51.000Z - 7 days ago

Novo Nordisk price target raised to $47 from $45 at BMO Capital

How Novo Nordisk's CEO Says He Is Shifting the Company's Perspective

Thu, 06 Aug 2026 05:49:00 -0400 - 7 days ago

How Novo Nordisk's CEO Says He Is Shifting the Company's Perspective

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

2026-08-05T23:20:01.000Z - 7 days ago

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook

2026-08-05T18:30:23.000Z - 8 days ago

Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook

European Stocks Subdued as HSBC and Novo Nordisk Lead Declines

2026-08-05T17:24:14.000Z - 8 days ago

European Stocks Subdued as HSBC and Novo Nordisk Lead Declines

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Wed, 05 Aug 2026 12:52:00 -0400 - 8 days ago

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Novo Nordisk Wins Dutch Court Injunction Against Compounded Semaglutide Nasal Spray

2026-08-05T16:27:04.000Z - 8 days ago

Novo Nordisk Wins Dutch Court Injunction Against Compounded Semaglutide Nasal Spray

Novo Nordisk Stock (NVO) Recovers as Earnings Surprise to the Upside

2026-08-05T14:45:33.000Z - 8 days ago

Novo Nordisk Stock (NVO) Recovers as Earnings Surprise to the Upside

LLY

Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case

Aug 5, 2026, 9:57 AM EDT - 8 days ago

Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case

NVO

Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals

Aug 5, 2026, 9:05 AM EDT - 8 days ago

Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals

NVO

Novo Nordisk Earnings Call Transcript: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 8 days ago

Novo Nordisk Earnings Call Transcript: Q2 2026

Novo Nordisk Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 8 days ago

Novo Nordisk Quarterly report: Q2 2026

Novo Nordisk Slides: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 8 days ago

Novo Nordisk Slides: Q2 2026

Novo Nordisk (NVO) Raises Guidance Amid Mixed Market Reactions

2026-08-05T10:32:28.000Z - 8 days ago

Novo Nordisk (NVO) Raises Guidance Amid Mixed Market Reactions

Novo Nordisk CEO addresses investors' high Wegovy pill expectations

Aug 5, 2026, 5:01 AM EDT - 8 days ago

Novo Nordisk CEO addresses investors' high Wegovy pill expectations

NVO

Novo Nordisk CEO addresses investors' high Wegovy pill expectations

2026-08-05T08:27:18.000Z - 8 days ago

Novo Nordisk CEO addresses investors' high Wegovy pill expectations

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Aug 5, 2026, 2:11 AM EDT - 8 days ago

Novo Nordisk's raised forecast fails to change the debate over its obesity business

NVO

Novo CEO faces investor grilling after outlook hike soured by pipeline concerns

Aug 5, 2026, 1:59 AM EDT - 8 days ago

Novo CEO faces investor grilling after outlook hike soured by pipeline concerns

NVO

Novo Nordisk AS (NVO) Shares Fall 6.0% -- What GF Score of 75 Tells Investors

2026-08-04T22:23:50.000Z - 8 days ago

Novo Nordisk AS (NVO) Shares Fall 6.0% -- What GF Score of 75 Tells Investors

Portal Innovations CEO John Flavin: Novo Nordisk is undervalued

2026-08-04T21:57:29.000Z - 8 days ago

Portal Innovations CEO John Flavin: Novo Nordisk is undervalued

Novo Nordisk (NVO) Raises Sales Guidance Amid Strong Demand for Weight Loss Drug

2026-08-04T20:13:38.000Z - 8 days ago

Novo Nordisk (NVO) Raises Sales Guidance Amid Strong Demand for Weight Loss Drug

The Wegovy pill's ‘surprise miss' is one reason Novo Nordisk's stock is down

Aug 4, 2026, 4:01 PM EDT - 8 days ago

The Wegovy pill's ‘surprise miss' is one reason Novo Nordisk's stock is down

NVO

Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes

Aug 4, 2026, 3:08 PM EDT - 9 days ago

Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes

NVO

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

2026-08-04T19:02:35.000Z - 9 days ago

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

Aug 4, 2026, 2:16 PM EDT - 9 days ago

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

NVO

Novo Nordisk reports earnings, lowers U.S. outlook

2026-08-04T17:45:34.000Z - 9 days ago

Novo Nordisk reports earnings, lowers U.S. outlook

Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day Early

2026-08-04T17:39:44.000Z - 9 days ago

Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day Early

Novo Nordisk shares slide after guidance disappoints investors

Aug 4, 2026, 1:30 PM EDT - 9 days ago

Novo Nordisk shares slide after guidance disappoints investors

NVO

Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost

Aug 4, 2026, 1:03 PM EDT - 9 days ago

Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost

NVO

Novo Nordisk's Q2 profit beats forecasts, raises outlook

Tue, 04 Aug 2026 12:41:34 -0400 - 9 days ago

Novo Nordisk's Q2 profit beats forecasts, raises outlook

Novo Nordisk reports Q2 adjusted sales DKK 78.49B, up 7% at CER

2026-08-04T16:40:32.000Z - 9 days ago

Novo Nordisk reports Q2 adjusted sales DKK 78.49B, up 7% at CER

Novo Nordisk raises FY26 adjusted sales view to 0% to down 6% from down 4%-12%

2026-08-04T16:40:25.000Z - 9 days ago

Novo Nordisk raises FY26 adjusted sales view to 0% to down 6% from down 4%-12%

5 Things to Know Before the Stock Market Opens on Monday

Aug 3, 2026, 8:10 AM EDT - 10 days ago

5 Things to Know Before the Stock Market Opens on Monday

AMD AZN BMY CAT CVS DASH DIS

Novo Nordisk sees optimism as Wegovy pill leads against Foundayo, Reuters says

2026-08-03T10:25:32.000Z - 10 days ago

Novo Nordisk sees optimism as Wegovy pill leads against Foundayo, Reuters says

Obesity battle heats up again as Novo claws way back into race with Lilly

Aug 3, 2026, 1:02 AM EDT - 10 days ago

Obesity battle heats up again as Novo claws way back into race with Lilly

LLY

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

2026-07-31T22:18:46.000Z - 12 days ago

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

2026-07-31T18:50:43.000Z - 13 days ago

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

BIOA GLUE

BioAge Labs price target lowered to $25 from $36 at Roth Capital

2026-07-31T18:40:22.000Z - 13 days ago

BioAge Labs price target lowered to $25 from $36 at Roth Capital

BIOA

Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss

2026-07-31T18:35:28.000Z - 13 days ago

Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss

GLUE

Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial

Jul 31, 2026, 11:15 AM EDT - 13 days ago

Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial

LLY

Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial

Jul 31, 2026, 10:56 AM EDT - 13 days ago

Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial

Novo Nordisk's stock slumps after failed trial — adding to the company's woes

Jul 31, 2026, 9:54 AM EDT - 13 days ago

Novo Nordisk's stock slumps after failed trial — adding to the company's woes

Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results

Jul 31, 2026, 9:17 AM EDT - 13 days ago

Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results

Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial

Jul 31, 2026, 8:02 AM EDT - 13 days ago

Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial

Novo Nordisk shares dive 9% after heart medicine fails trial

Jul 31, 2026, 7:43 AM EDT - 13 days ago

Novo Nordisk shares dive 9% after heart medicine fails trial

Novo Nordisk's inflammation drug fails to reduce cardiovascular risk in trial

Jul 31, 2026, 7:34 AM EDT - 13 days ago

Novo Nordisk's inflammation drug fails to reduce cardiovascular risk in trial

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Jul 29, 2026, 9:11 AM EDT - 15 days ago

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Novo Nordisk must face US shareholder lawsuit over CagriSema clinical trial

Jul 28, 2026, 1:00 PM EDT - 16 days ago

Novo Nordisk must face US shareholder lawsuit over CagriSema clinical trial

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

Jul 24, 2026, 9:09 AM EDT - 20 days ago

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

LLY

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

Jul 24, 2026, 5:48 AM EDT - 20 days ago

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

LLY

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Jul 24, 2026, 4:41 AM EDT - 20 days ago

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

LLY

Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications

Jul 23, 2026, 9:01 AM EDT - 21 days ago

Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications

Weight loss drugs linked to increase risk of hair loss

Jul 22, 2026, 8:57 PM EDT - 21 days ago

Weight loss drugs linked to increase risk of hair loss

LLY

Hair loss with GLP-1 drugs is rare, but real, studies find

Jul 22, 2026, 6:31 PM EDT - 21 days ago

Hair loss with GLP-1 drugs is rare, but real, studies find

AZN LLY

Many US patients opt for obesity drug injections, defying some expectations

Jul 22, 2026, 6:06 AM EDT - 22 days ago

Many US patients opt for obesity drug injections, defying some expectations

LLY

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

Jul 21, 2026, 10:29 AM EDT - 23 days ago

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

LLY

Novo Sues Rival Lilly Over Weight-Loss Ads

Jul 21, 2026, 10:21 AM EDT - 23 days ago

Novo Sues Rival Lilly Over Weight-Loss Ads

LLY

Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising

Jul 21, 2026, 9:15 AM EDT - 23 days ago

Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising

LLY

Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims

Jul 21, 2026, 8:33 AM EDT - 23 days ago

Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims

LLY

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications

Jul 21, 2026, 8:18 AM EDT - 23 days ago

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications

LLY

Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs

Jul 21, 2026, 7:58 AM EDT - 23 days ago

Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs

LLY

Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Jul 21, 2026, 7:38 AM EDT - 23 days ago

Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

LLY

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Jul 21, 2026, 7:35 AM EDT - 23 days ago

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

LLY

One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends

Jul 18, 2026, 4:00 PM EDT - 25 days ago

One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends

LLY

Novo Nordisk to launch lower-cost Ozempic copy in South Africa

Jul 17, 2026, 12:20 PM EDT - 27 days ago

Novo Nordisk to launch lower-cost Ozempic copy in South Africa

India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease

Jul 17, 2026, 4:39 AM EDT - 27 days ago

India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease

Novo Nordisk wins EU approval for Wegovy weight-loss pill

Jul 15, 2026, 12:40 PM EDT - 4 weeks ago

Novo Nordisk wins EU approval for Wegovy weight-loss pill

Ad7777
Ad7777 Aug. 13 at 7:33 PM
$NVO x dividends fri.
0 · Reply
Jtlo
Jtlo Aug. 13 at 7:22 PM
$NVO wegovy baby shag daddy is here to turn things around
0 · Reply
Pfiffer
Pfiffer Aug. 13 at 7:22 PM
$NVO powerhour
0 · Reply
Jtlo
Jtlo Aug. 13 at 7:15 PM
$NVO 12 months don't shake me out. My girl on too much novy and look hella fine for me to be broke
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 6:11 PM
$LXRX $NVO $VTRS Dr Edelman is total proponent of Zynquista for T1 - A towering authority in his field, that completely has our back = $LXRX
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 5:19 PM
$LXRX watch: Lexicon is exhibiting at TCOYD [Taking Control Of Your Diabetes] ONE 2026, Aug 14-16, San Diego. TCOYD is led by Dr. Steve Edelman (Founder/Director, UCSD Prof. of Medicine) and Dr. Jeremy Pettus (UCSD Assoc. Prof.) — independent physicians, not Lexicon staff, but longtime T1D [type 1 diabetes] advocates for options beyond insulin. Fresh catalyst: on Lexicon's Q2 2026 call, mgmt said STENO1 (Steno Diabetes Center, Denmark) is nearing the exposure threshold FDA flagged as sufficient for NDA [New Drug Application] resubmission of Zynquista (sotagliflozin) in T1D. Exposure expected by end of Aug 2026; DKA [diabetic ketoacidosis] rates similar to standard-of-care, below earlier trials. Resubmission targeted Q4 2026. Watching conference + STENO1 data into Q4. NFA. DYOR. https://www.linkedin.com/posts/lexicon-pharmaceuticals_lexicon-t1d-dpnp-activity-7493668586708885504-LpTh?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA $VTRS $NVO
0 · Reply
HerrBroekman
HerrBroekman Aug. 13 at 4:46 PM
$NVO bought some jan calls here
0 · Reply
Makingmillions192
Makingmillions192 Aug. 13 at 4:36 PM
$LEXX PegBio is not a tiny micro-cap shell company or early-stage startup—they are a $300M+ market-cap GLP-1 drug owner with a newly approved commercial molecule and US clinical trials. Having a funded partner evaluating DehydraTECH for their portfolio gives Lexaria substantial real-world validation. Hold onto your seats ladies and gentlemen. Lexaria is here 🔥 $VKTX $LLY $RANI $NVO
0 · Reply
Makingmillions192
Makingmillions192 Aug. 13 at 4:31 PM
🚀 $LEXX BOOOOM! 🚨 SECOND GLP-1 MTA CONFIRMED! 🚀 This is NOT a drill. Lexaria just dropped a game-changer! Entered into a brand-new Material Transfer Agreement (MTA) with PegBio to process their proprietary GLP-1 molecule via DehydraTECH! 🔥 THE HIGHLIGHTS: 1️⃣ Separate & Independent: This is IN ADDITION to the existing MTA partner. DehydraTECH pipeline is expanding! 2️⃣ Commercial Validation: PegBio has a GLP-1 approved in China (Nov 2025) + Phase 2 assets in US/China across Obesity, Diabetes, & MASH! 3️⃣ Liberi Group BD Delivering: The advisory strategy is executing in REAL TIME. Human trial data drops any day now ⏰ TICK TOCK 💥 🧨 Sub-1.65M float + massive BD validation + Study #7 data dropping next! We are SO BACK! 📈🔥 $VKTX $LLY $NVO $PFE
0 · Reply
Eddyg987
Eddyg987 Aug. 13 at 4:00 PM
$NVO ok at this point it doest look like it's going to move until next earnings, getting out until I see movement.
0 · Reply
DG20
DG20 Aug. 13 at 2:55 PM
$NVO $VKTX Bloomberg is effectively treating Viking as one of the principal competitive threats to Novo, despite Viking having no commercial obesity product today.
1 · Reply
Pseudominds
Pseudominds Aug. 13 at 2:52 PM
$NVO do nothing, I will sit and wait. Afterall my thesis already concluded this look like a fallen angel.
0 · Reply
russlanramdowar
russlanramdowar Aug. 13 at 2:42 PM
https://stocktwits.com/news-articles/markets/equity/nvo-stock-jumps-3-as-eu-approves-oral-wegovy-pill-retail-notes-lly-is-clearly-behind-its-danish-counterpart/cZZPaw9R7r9 $NVO The EU approval widens $NVO's addressable oral market, but my thesis is about volume economics, not approval headlines alone. Q2 adjusted sales grew 7% at constant exchange rates and weekly Wegovy pill prescriptions exceeded 265,000, while full-year adjusted sales and operating-profit growth still guides to 0% to -6%. My test is whether oral and international volume can outrun price and margin compression and convert into cash. Long $NVO. Research view, not advice.
0 · Reply
sexycarrot22
sexycarrot22 Aug. 13 at 2:35 PM
$NVO
0 · Reply
russlanramdowar
russlanramdowar Aug. 13 at 1:56 PM
Highest-ranked Stocktwits-supported names in my Aug. 13 one-year equity screen: $NVO - GLP-1 volume must offset price and margin compression. $PGR - telematics plus fast repricing must preserve a sub-90 combined ratio. $TTD - the highest-upside and highest-risk case; CTV and retail-media growth must outrun ad-cycle and execution pressure. Model research, not recommendations. Long $NVO and $TTD; no position in $PGR.
0 · Reply
snidely
snidely Aug. 13 at 12:57 PM
$NVO At this point I think the company wants to keep the share price low because 99% of investors will sell even at the chance
2 · Reply
YuhhhhhU
YuhhhhhU Aug. 13 at 12:51 PM
$NVO if u invested into this stock 5 years ago you’d basically have your initial investment less inflation lmao. Something’s gotta change here.
0 · Reply
stklover
stklover Aug. 13 at 12:44 PM
$NVO CEO seems very cocky. I don’t like the guy. Will buy the stock (1) if he leaves, or (2) an activist gets involved. Stock should be much higher. Why isn’t it?
1 · Reply
Kocatka
Kocatka Aug. 13 at 12:34 PM
$LXRX $NVO Bolt On = Sotagliflozin. Get it done!
0 · Reply
Kocatka
Kocatka Aug. 13 at 12:30 PM
$LXRX $NVO NOVO Nordisk Capital Markets Day September 21st. Right now it doesn't look to promising for '27. Do they get a deal signed for Sotagliflozin and Typre 1 Diabetes prior to this date?
0 · Reply
SniperPro
SniperPro Aug. 13 at 12:26 PM
🚀 $LXRX — The setup is becoming VERY hard to ignore. Part 2 🤑 This isn't just a “one drug” biotech anymore. It's commercial revenue + regulatory catalysts + global distribution + multiple Phase 3 shots + a Novo-backed obesity asset + rapidly growing institutional interest. And the beauty of the setup? LXRX doesn't need everything to hit. If ZYNQUISTA wins, HCM wins, Novo's program works, or another partnership lands, the valuation could look very different. The market sees a small biotech. I see a cardiometabolic platform with multiple ways to win. 🚀 The story is just getting started. Putting the pieces together, I think Lexicon is increasingly becoming an asymmetric cardiometabolic story. $LXRX $BLK $STT $VOO $NVO ...
0 · Reply
SniperPro
SniperPro Aug. 13 at 12:24 PM
🚀 $LXRX — The setup is becoming VERY hard to ignore. Part 1 🤑 The pieces are lining up: 🔥 Institutional accumulation: ~17M+ BlackRock + ~4.5–5M State Street shares, alongside major increases from Point72, Renaissance, Marshall Wace, Jane Street, Susquehanna & Geode. 💊 ZYNQUISTA: potential U.S. approval + major commercial opportunity. 🌎 Viatris: global commercialization infrastructure for sotagliflozin outside U.S./Europe. ❤️ SONATA-HCM: Phase 3, with topline data targeted for Q1 2027. 🤝 Novo Nordisk: worldwide LX9851 deal with up to $1B in potential milestones + royalties — massive validation and obesity optionality. 🧬 Pilavapadin: another potential partnering/Phase 3 catalyst. $LXRX $BLK $STT $VOO $NVO ...
0 · Reply